Practice guidelines

Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society

C. Lebrun, S. Vukusic, Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, hospices civils de Lyon, 69677 Bron, France
C. Lebrun, S. Vukusic, Observatoire français de la sclérose en plaques, Centre de recherche en neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, 69003 Lyon, France
C. Lebrun, S. Vukusic, Université de Lyon, université Claude-Bernard Lyon 1, 69000 Lyon, France
C. Lebrun, S. Vukusic, Eugène Devic EDMUS Foundation against multiple sclerosis, state-approved foundation, 69677 Bron, France

ABSTRACT

Objectives. – To establish recommendations on immunization for patients with multiple sclerosis (MS).

Background. – Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients.

Methods. – The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975–June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain.

Results. – Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule

INFO ARTICLE

Article history:
Received 30 March 2019
Received in revised form 31 March 2019
Accepted 11 April 2019
Available online 27 April 2019

Keywords:
Multiple sclerosis
Immunization
Vaccine
Infection
Prevention
1. Introduction

Multiple sclerosis (MS) is an autoimmune disease in which all players in the inflammatory repertory react against myelin antigens. Autoreactive T cells, monocytes, and the more recently demonstrated B cells contribute to the pathophysiology. The suggestion that vaccines might be a generator of MS or a triggering factor of relapse has given rise to passionate debate. In France, the controversy over the link between vaccination against hepatitis B (HBV) and the occurrence of MS was particularly strong in the 1990s. Several formal consensus agreements and expert auditions were organized by the French health authorities between 2001 and 2011, leading to the conclusion of the absence of evidence of a causal association between HBV vaccine and MS or central nervous system (CNS) demyelinating events [1–4]. In parallel, experts pointed out an ‘ambivalence’ perceived by the general public in the legal analysis of post-vaccination events: on one hand, a clearly identified framework for compulsory vaccination of health professionals allowed recognition of a presumption of accountability, that can lead to compensation; on the other hand, in all other cases, the absence of scientific evidence in favour of a causal relation results in an impossibility of satisfying a claim for compensation. The confusion and uncertainty around this debate have reached the general public as well as many health professionals and is an obstacle for vaccinating subjects who should be vaccinated.

In 2017, the French Multiple Sclerosis Society (Société francophone de la sclérose en plaques [SFSEP]) decided to initiate a task force to establish recommendations on immunization of MS patients, considering that:

- reluctance to vaccinate persists, both for patients and health professionals, decreasing vaccination coverage in the general population, but especially in the family members of patients suffering from MS;
- the therapeutic arsenal for MS has been considerably enriched and many new DMTs are now available. In this context, questions arose on the effectiveness of vaccines in patients exposed to these new drugs, as well as on the most adapted application of the vaccination schedule and on the prevention of potential infectious risks induced by these treatments [5];
- important data on vaccination have been acquired in the last decade from patients with other autoimmune disorders, allowing extrapolation to MS.

2. Methods

The methodology of studies into the relationship between vaccines and specific disease risk rarely provides a high level of evidence. Randomized trials are only feasible in practice to answer questions such as the risk of triggering a relapse after vaccination or the evaluation of the biological efficacy of a vaccine while on DMT. In contrast, evaluation of the risk of MS after vaccination would require a prospective follow-up of cohorts of dozens or even hundreds of thousands of exposed and unexposed individuals, because of a weak to moderate association, for a low prevalence disease (1 per 1000). There are numerous other methodological limitations in the current literature, including heterogeneous case definition, questionable quality of data collection and validation and variable exposure intervals.

The abundance of scientific literature containing methodological limitations that do not allow a conclusion to be reached justifies the methodological choice to formulate recommendations by formalized consensus (RAND) according to the recommendations of the French High Authority of Health (Haute Autorité de Santé [HAS]) [6].

The “Formal consensus” method is both a method for development of good practice guidelines and a consensus method, derived from the RAND/UCLA Appropriateness method [7]. Its main objective is to formalize the degree of agreement among experts by identifying and selecting, through iterative ratings with feedback, the points on which experts agree and on which the recommendations are secondarily based, and the points on which experts disagree or are undecided, to provide professionals and patients with assistance in deciding on the most appropriate care in given clinical circumstances.

The Steering Committee defined 5 clinical questions within the scope of the recommendations:

- Are vaccines associated with an increased risk of MS?
- Are vaccines associated with an increased risk of relapse in MS or a worsening of disability?
• Are vaccines as effective in people with MS as in the general population (regardless of treatment)?
• Are vaccines as effective in people with MS exposed to disease-modifying treatments?
• What methods of prevention should be offered to patients with MS?

The literature search for publications in English and French was performed with the help of professional librarians, using the Medline database (http://www.ncbi.nlm.nih.gov/pubmed), the main websites referencing publications on recommendations and consensus conferences, and grey literature. An initial search was made with the following keywords: multiple sclerosis, central nervous system demyelination, clinically isolated syndrome, optic neuritis, vaccination, vaccine, relapse, infection, immunomodulators, immunosuppressants, interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, fingolimod, natalizumab, cyclophosphamide, methotrexate, cladribine, ocrelizumab, rituximab, alemtuzumab, campath, azathioprine, mycophenolate. A subsequent search was done by analyzing the references of each selected paper.

Readers from the steering committee then conducted a systematic analysis of the literature using reading grids and wrote a critical and hierarchical synthesis of the literature, including a referenced text and summary tables with mention of the levels of evidence of the studies. Members of the steering committee met to discuss the evidence reported and to prepare the list of proposals to be submitted to the rating group. Proposals were classified into levels A, B, or C according to the HAS guidelines (Table 1). In the absence of sufficient data, the proposed recommendations corresponded to an expert agreement only. In the absence of expert agreement, the alternatives were exposed without any recommendations in favour of one or the other.

Thereafter, proposals were submitted to a rating group that did not participate in the initial drafting. Each rater had to decide on his/her level of agreement with each proposal, giving a score between 1 (total disagreement) and 9 (total agreement). All members of the steering committee and rating group collaborated in the drafting of the final recommendations during a face-to-face meeting.

A reading group made of neurologists and other health care professionals was asked to review the final version of the recommendations, giving a score between 1 (total disagreement) and 9 (total agreement) and making comments. Proposals were then classified as appropriate (median value ≥ 7), inappropriate (median value < 3.5) or uncertain (median value 4–6.5), with a different degree of agreement (Table 2).

After analysis and discussion of ratings and comments made by the reading group, initial recommendations were modified according to the following rules:

• recommendations based on a high level of evidence (level A or B): consideration of relevant comments to improve the form, changes to the content, if any, based on data provided, changing the level of the recommendation if necessary;
• recommendations based on a level of evidence (level C) or on agreement within the rating group: when the reading group confirmed the appropriate nature of the recommendation (≥ 90% of responses from the reading group within the range [5–9]), the recommendation was retained and relevant comments were considered to improve the form, when the reading group was more widely undecided or disagrees with the initial recommendation (< 90% of responses from the reading group within the range [5–9]), the steering group, after debate with the rating group, proposed possible modifications based on comments or the rejection of the recommendation.

3. Results

An extensive French version of the summary of evidence, including tables with mention of the levels of evidence of the studies, is available on the website of the SFSEP (www.sfsep.org) or upon request to the authors. A summary of the recommendations is presented in Table 3. Detailed results of the final ratings are provided in Appendix B.

3.1. Question 1: Are vaccines associated with an increased risk of MS?

| Recommendation 1. Vaccines, in general, are not associated with an increased risk of MS or occurrence of a first demyelinating episode of the central nervous system, including hepatitis B and human papillomavirus vaccines (level B) |
Rating: Appropriate (number of available scores: 71; 100% [5–9]; Relative agreement (median 8, min–max 5–9, 30th–70th percentile: 8–9).

The question of vaccinations as a risk factor for the occurrence of MS was first studied in a general way and then vaccine-by-vaccine. Available studies generally evaluate the association between one or more vaccination and the risk of a first episode of demyelination in the CNS rather than MS. This definition of cases may cover first episodes of MS, not fulfilling, at the time of the study, the diagnostic criteria for MS, but also other clinical situations that may not evolve later into MS (idiopathic inflammatory optic neuritis, disseminated acute encephalomyelitis).

### 3.1.1. All vaccines

Two class 3 studies found an odds ratio (OR) of 1.4 [95% confidence interval (CI) 0.5–4.3], respectively for any vaccination in the last 60 days (2.1 [0.7–6.0] between 61 and 180 days) and 1.03 [0.86–1.22] for any vaccination in the last 3 years [8,9].

No study provided evidence for an increased risk of MS after any vaccination.

### 3.1.2. Hepatitis B (HBV)

Twelve studies, all class 3, published between 1999 and 2014, studied the risk of developing MS after HBV vaccination; two cohorts, and ten case-control studies, some nested within pre-existing cohorts. Four studies were conducted in France [8,10–12], four in the USA [9,13–15], two in Canada [16,17], one in Iran [18] and one in the United Kingdom [19]. Three studies [11,12,16] (two in France and one in Canada) focused specifically on the risk in children and adolescents.

One study only found a significant association between HBV vaccination and the occurrence of MS within 3 years, among 163 cases and 1604 matched controls, with an OR of 3.1 [1.5–6.3] [19]. However, strong methodological limitations questioned this result, in the context of a large number of other studies with negative results that appeared to be more robust. Therefore, it can be concluded that there is currently no evidence for an association between vaccination against HBV and the occurrence of MS, regardless of the time interval studied. This result is reinforced by a meta-analysis published in 2018, that confirmed the absence of an association between HBV vaccination and the occurrence of MS (OR = 1.19 [0.93–1.52]) or the first episode of CNS demyelination (OR = 1.25 [0.97–1.62]) [20].

### 3.1.3. Human Papilloma Virus (HPV)

There are seven reported studies, all class 2 to 3, 3 cohorts [21–23], 3 case-control studies [9,24,25] and 1 pooled analysis of clinical trials [26], studying the association between vaccination against HPV and the occurrence of MS or the first episode of CNS demyelination.

Overall, these studies did not find any association, and two French studies even reported significant protection.

### 3.1.4. Influenza

Four case-control studies (class 3) assessed the association between seasonal influenza vaccination and the occurrence of MS or a first CNS demyelinating episode [15,17,19,27]. Data on seasonal influenza vaccination were secondary analyses in all cases; the studies were designed to evaluate the risk associated with all vaccines or HBV only.

None of these studies provided evidence for an association. Two additional studies focused specifically on H1N1 vaccination during the 2009–2010 pandemic and did not find any association [28,29].

There is no argument for an increased risk of developing MS after vaccination with the H1N1 strain of the influenza virus.

### 3.1.5. Measles-Mumps-Rubella (MMR)

Several studies (all class 3) evaluated measles, mumps and rubella vaccines, alone or in combination, together with other risk factors and/or other vaccines [15,17,27,30–31].

Only the study by Zorzon et al. [27] found a significant association, especially for measles vaccination anytime in the past, with a very unusually high crude OR of 50.4 [6.8–373.3] and adjusted OR 92.2 [12.1–700.2]. The crude ORs were also very high for all the other vaccines studied (51.4 [6.9–381.2] for mumps, 6.2 [2.3–15.3] for rubella), but the adjusted OR, not provided in the publication, were not significant for these two vaccines. These unusual and discordant results compared to those of the other available studies suggest potential methodological bias. In particular, the percentages of exposure to
Table 3 – Summary of the Recommendations of the French Multiple Sclerosis Society (SFSEP) on immunization and multiple sclerosis (MS).

<table>
<thead>
<tr>
<th>Questions</th>
<th>Responses</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Question 1: Are vaccines associated with an increased risk of MS?</td>
<td>1. Vaccines, in general, are not associated with an increased risk of MS or occurrence of a first demyelinating episode of the central nervous system, including hepatitis B and human papillomavirus vaccines.</td>
<td>Level B</td>
</tr>
</tbody>
</table>
| Question 2: Are vaccines associated with an increased risk of relapse or worsening of disability in MS? | 2a. Vaccines, in general, are not associated with an increased risk of relapse in patients with MS. An increased risk of relapse after vaccination against yellow fever cannot be excluded.  
2b. Influenza and BCG vaccines have no impact on the short-term accumulation of disability. Impact of other vaccines on disability has not been studied yet. | Level B         |
| Question 3: Are vaccines as effective in people with MS as in the general population (regardless of treatment)? | 3. Available data on the efficacy of inactivated vaccines, in patients with MS and without disease-modifying treatment suggest that it is similar to the general population, particularly for mono- and trivalent influenza vaccines. No studies are available for live attenuated vaccines. | Level C         |
| Question 4: Are vaccines as effective in people with MS exposed to disease-modifying treatments? | 4a. Interferon beta. The vaccine response to influenza of patients treated with interferon beta is not decreased compared to healthy controls and untreated MS. The vaccine response to Meningococcus, Pneumococcus, and Diphtheria-Tetanus, in patients treated with interferon beta, is not decreased compared to healthy controls and untreated MS. The other vaccines were not studied.  
4b. Glatiramer acetate. The vaccine response to influenza in patients with MS treated with glatiramer acetate may be reduced compared to healthy controls and untreated MS. The other vaccines were not studied.  
4c. Dimethylfumarate. The vaccine response to Meningococcus, Pneumococcus and diphtheria-tetanus vaccines in patients with MS treated with dimethylfumarate appears to be comparable to that of MS treated with interferon beta. Due to the risk of lymphopenia it is advised to apply immunization recommendations for immunocompromised patients.  
4d. Teriflunomide. The vaccine response to influenza in patients treated with teriflunomide is decreased compared to MS treated with interferon beta. The other vaccines were not studied. It is advised to apply immunization recommendations for immunocompromised patients.  
4e. Mitoxantrone. The vaccine response to influenza in patients treated with mitoxantrone is insufficient compared to healthy controls. The other vaccines were not studied. It is advised to apply immunization recommendations for immunocompromised patients.  
4f. Natalizumab. The vaccine response in patients treated with natalizumab is reduced for influenza, but not for tetanus, compared to healthy controls. | Level B         |
Table 3 (Continued)

<table>
<thead>
<tr>
<th>Questions</th>
<th>Responses</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>The other vaccines were not studied</td>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>4g. Fingolimod</td>
<td>The vaccine response in patients treated with fingolimod is reduced compared to healthy controls, untreated MS and interferon beta-treated patients</td>
<td>Level B</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>4h. Alemtuzumab</td>
<td>The data are insufficient to evaluate the vaccine response in patients treated with alemtuzumab</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Level B</td>
<td></td>
</tr>
<tr>
<td>4i. Ocrelizumab</td>
<td>The vaccine response in patients treated with ocrelizumab is effective but decreased after 12 weeks for tetanus, Pneumococcus and influenza compared with non-treated and interferon beta-treated MS</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Level B</td>
<td></td>
</tr>
<tr>
<td>4j. Cladribine</td>
<td>No vaccine has been studied in patients with MS treated with cladribine</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>4k. Cyclophosphamide (off-label)</td>
<td>No vaccine has been studied in patients with MS treated with cyclophosphamide</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>4l. Methotrexate (off-label)</td>
<td>No vaccine has been studied in patients with MS treated with methotrexate</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>The vaccine response in patients with rheumatoid arthritis treated with methotrexate is satisfactory</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>4m. Azathioprine/mycophenolate mofetil (off-label)</td>
<td>No vaccine has been studied in patients with MS treated with azathioprine or mycophenolate mofetil</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>4n. Rituximab and other anti-CD20 (off-label)</td>
<td>No vaccine has been studied in patients with MS treated with rituximab and other anti-CD20 (except ocrelizumab)</td>
<td>Expert recommendation</td>
</tr>
<tr>
<td>It is advised to apply immunization recommendations for immunocompromised patients</td>
<td>Expert recommendation</td>
<td></td>
</tr>
<tr>
<td>Question 5: What prevention methods should be offered to patients with MS?</td>
<td>5a. The vaccination schedule of the general population should be applied to any patient with MS unless there is a specific contraindication</td>
<td>Recommendation of the Haut Conseil de la Santé Publique, article L. 3111-1, Code de la Santé Publique</td>
</tr>
</tbody>
</table>
vaccines were much higher in cases than in controls, suggesting reporting bias with over-reporting in cases and under-reporting in controls, especially since the vaccination was not verified, neither for presence nor for absence of vaccines.

In conclusion, an increased risk of MS after vaccination against combined MMR or against each of the 3 viruses seems unlikely.

3.1.6. Diphtheria-tetanus-pertussis-polioymelitis
No study has specifically evaluated the association between these vaccinations, used alone or in combination, and the occurrence of MS or a first CNS demyelinating episode.

Six case-control studies (class 3) are available [15,19,27,30,31,33].

There are no arguments to support the hypothesis of an increased risk associated with any of the vaccinations against diphtheria, tetanus, pertussis or poliomyelitis.

3.1.7. Other vaccinations
There is insufficient data in the literature to conclude on the potential risks related to other vaccines; studies are either lacking or insufficiently powered. However, there is no signal described for vaccines against meningococcus, pneumococcus, varicella/zoster virus, yellow fever, typhoid, and BCG.

3.2. Question 2: Are vaccines associated with an increased risk of relapse in MS or of worsening of disability?

Recommendation 2a. Vaccines, in general are not associated with an increased risk of relapse in a patient with MS (level B). An increased risk of relapse after vaccination against yellow fever cannot be excluded (level C)

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Relative agreement (median 9, min–max 6–9, 30th–70th percentile: 8–9).

Recommendation 2b. Influenza and BCG vaccines have no impact on the short-term accumulation of disability (level C). The impact of other vaccines on disability has not been studied yet

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Strong agreement (median 9, min–max 7–9, 30th–70th percentile: 8–9).
3.2.1. All vaccines
One study only focused specifically on the risk of relapse after any vaccination in MS patients [34]. This was a case-crossover study (the patient was his own control, a period of two months followed by a relapse being compared to 4 control periods of the same duration, not followed by relapse, taken during the previous year) (class 2 or 3). The relative risk (RR) of exposure to any vaccination was 0.71 [0.40–1.26]. Sensitivity analyses for different periods (1 and 3 months) and according to the confirmation or not of the vaccine also found non-significant RRs. It can be concluded that there is no evidence for an association between vaccination and MS relapse.

3.2.2. Influenza
The literature on seasonal influenza and H1N1 vaccination is the richest, with a placebo-controlled randomized clinical trial [35] (class 1 or 2) and a series of cases with close MRI follow-up after vaccination [36].

In conclusion, available data on seasonal influenza vaccination does not support an increased risk of relapse and disability in MS patients, and the level of evidence for relapse is relatively high, with a randomized trial and little, but confirmatory MRI data. For the H1N1 strain, the positive results of one isolated small study [37] do not seem enough to counterbalance the negative results of all the other studies.

3.2.3. Hepatitis B
The only available data is a subgroup analysis of the VACCIMUS study, with an RR of 0.67 [0.20–2.17] [34]. There is no information on the evolution of disability.

3.2.4. Measles-Mumps-Rubella (MMR)
No study has analyzed the risk of relapse and/or progression of disability following MMR vaccination.

3.2.5. Diphtheria-tetanus-pertussis-polioymelitis
The only available data is a subgroup analysis of the VACCIMUS study, with a RR of 0.22 [0.05–0.99] for the combined vaccine and 0.75 [0.23–2.46] for tetanus alone [34]. There is no information on the evolution of disability.

3.2.6. BCG
Two studies by the same group [38,39], including one randomized class 1 trial, found a significant decrease in MRI activity (RR for new gadolinium-enhancing T1 lesions = 0.54 [0.31–0.96], new or enlarging T2 lesions = 0.36 [0.21–0.64] and new T1 lesions = 0.15 [0.05–0.42] in BCG vaccinated compared to controls). Clinical results were confirmative, with a reduction in the risk of conversion to definite MS at 60 months (RR = 0.52 [0.27–0.99]). The change in disability measured by EDSS was similar in both groups at 6 months.

Overall, there is strong evidence for the absence of risk of relapse associated with BCG vaccination, with even a decrease in this risk. In addition, BCG does not seem to change the evolution of disability in the short-term.

3.2.7. Yellow fever
A single study on yellow fever vaccination is available [40] (class 4 because of the small number of patients), including 7 relapsing-remitting MS (RRMS) patients followed clinically prospectively every 3 months with MRI, and matched with 7 healthy controls and 7 RRMS patients vaccinated for influenza over the same period of time. The RR was found significantly increased over the 1 to 5 weeks at-risk period (12.78 [4.28–38.13]) with an increase in the mean number of new or enlarging T2 lesions and gadolinium-enhancing T1 lesions.

It is difficult to draw firm conclusions from a single, small study, even though the clinical results were confirmed by radiological data and the evolution of a control group that received the influenza vaccine. An increase in the risk of relapse after vaccination against yellow fever cannot be ruled out.

3.2.8. Other vaccines
No conclusions can be drawn for other vaccinations because of the small amount or total absence of data.

In conclusion, vaccines, in general, do not appear to increase the risk of relapse in patients with MS. This has been particularly well studied for influenza and BCG. Only an isolated, well-documented, but small-sized study, reported an increased risk of relapse with the yellow fever vaccine.

There is no worsening of disability after vaccination against influenza or BCG, the only two vaccines for which data are available.

It should be underlined that in the reported studies, vaccines were not administered close to relapse.

3.3. Question 3: Are vaccines as effective in people with MS as in the general population (regardless of treatment)?

Recommendation 3. Available data on the efficacy of inactivated vaccines, in patients with MS and without disease-modifying treatment, suggest that it is similar to the general population, particularly for mono- and trivalent influenza vaccines (level C). No studies are available for live attenuated vaccines

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Strong agreement (median 9, min–max 7–9, 30th–70th percentile: 8–9).

There are limited means to detect the biological effect of vaccines. Most assays are humoral based, but some of the protection provided by vaccines is also conveyed by T cells, which typically cannot be studied with commercially available assays. Therefore, the efficacy of a vaccine can be evaluated either biologically by measuring the titres of specific antibodies in the blood, suggestive of appropriate protection, or clinically by the incidence of the infectious disease. Only 6 studies have analyzed the efficacy of vaccination in untreated MS patients [36,41–45]. These were small-sized studies that primarily analyzed the change in antibody levels against the target pathogen. Two of these studies showed a significant increase in the level of antibodies against the varicella virus and the virus responsible for tick-borne encephalitis [41,42], although it was not clear whether protective titres were reached. Two other studies showed an increase in antibody titres after trivalent vaccination for seasonal influenza and a similar or even higher T-cell response in patients with MS than
in the control population [36,43]. Two cohort studies also showed that antibody titres were as high as in healthy controls after one injection of the H1N1 strain [44] (percentage of protected patients at 3 months, 92.9% vs. 94.0%) [45].

No study was found regarding the response to live attenuated vaccines in MS patients.

3.4. Question 4: Are vaccines as effective in people with MS exposed to disease-modifying treatments?

**Recommendation 4a. Interferon beta.** The response to influenza vaccines of patients treated with interferon beta was not decreased compared to healthy controls and untreated MS patients (level B). The response to the vaccines against Meningococcus, Pneumococcus, and Diphtheria-Tetanus, in patients treated with interferon beta, was not decreased compared to healthy controls and untreated MS patients (level C). The other vaccines were not studied.

Rating: Appropriate (number of available scores: 67; 99% [5–9]); Relative agreement (median 9, min–max 3–9, 30th–70th percentile: 8–9).

The effectiveness of the influenza vaccine in interferon beta (IFNβ)-treated MS patients was evaluated in 5 studies, two of which compared the response to the H1N1 vaccine in healthy controls [45,46]. Seroprotection titers were reached in 88.0 and 97.7% of IFNβ-treated MS patients [45,46]. In another study, the proportion of patients with protective titers was not statistically different between treated and untreated patients after one dose of the trivalent influenza vaccine but varied among the strains of the vaccine [47]. The pooled analysis found an OR of 1.6 [1.03–2.48], indicating greater protection in patients treated with IFNβ. The fourth study compared patients on IFNβ with healthy controls [48]. At 4 weeks, the percentage of patients fulfilling seroprotection criteria was respectively in IFNβ patients and controls, 100% vs 78% for strain A (OR = 14 [0.76–259]), 100% vs 82% for strain B (OR = 26 [1.4–468]). Finally, in a study conducted during the 2009–2010 vaccination campaign against the H1N1 influenza pandemic, 44% of the 36 IFNβ-treated patients had protective titers compared to 43.5% of healthy controls (OR = 1.03 [0.5–2.1] after 10 months [44].

The response to Meningococcus, Pneumococcus, and Diphtheria-Tetanus has been evaluated in a study designed for another treatment, but with patients treated with interferon beta as one control group, beside healthy controls and untreated MS patients [49]. The response to other vaccines has not been studied with IFNβ-treated patients.

**Recommendation 4b. Glatiramer acetate.** The vaccine response to influenza in patients with MS treated with glatiramer acetate may be reduced compared to healthy controls and untreated MS patients (level C). The other vaccines were not studied.

Rating: Appropriate (number of available scores: 65; 94% [5–9]); Relative agreement (median 8, min–max 3–9, 30th–70th percentile: 8–9).

Two studies from the same team reported conflicting results. The first compared the effectiveness of vaccination against the influenza A virus in MS patients receiving different treatments, including 37 with glatiramer acetate (GA), versus 216 healthy controls [44]. The number of patients with persistent protective haemagglutination titers (≥ 40) was lower in patients on GA than in controls for H1N1 vaccination in 2009 (21.6% vs 43.5%), H1N1 in 2010 (58.3% vs 71.2%) and H3N2 in 2010 (41.7% vs. 79.5%). In a second similar study, conducted after the injection of a trivalent influenza vaccine (H1N1 and H3N2 strains) in 2012, 53 healthy subjects and MS patients treated with different DMTs including 23 on GA were compared [45]. There was no significant difference in the level of protection from H1N1 in patients treated with GA compared to controls at 3, 6 and 12 months, but a decreased level of protection was found for the H3N2 strain at 3 months in GA patients compared to untreated patients and healthy controls (21.6, 42.9 and 69.6% respectively).

These data indicate that for MS patients treated with GA the trivalent influenza vaccine was effective but may provide a lower level of protection than for healthy subjects.

The response to other vaccines has not been studied under GA.

**Recommendation 4c. Dimethylfumarate.** The vaccine response to Meningococcus, Pneumococcus and Diphtheria-Tetanus vaccines in patients with MS treated with dimethylfumarate appears to be comparable to that of MS patients treated with interferon beta (level C). Due to the risk of chronic lymphopenia, it is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 65; 98% [5–9]); Relative agreement (median 9, min–max 1–9, 30th–70th percentile: 8–9).

A single open-label, multicenter study compared the responses to different vaccines in MS patients treated with dimethylfumarate (DMF) (38 patients) or IFNβ (33 patients) (class 2) [49]. They received successively 3 types of vaccines: a diphertheria-tetanus vaccine to test the T-cell dependent memory response; a 23-valent pneumococcal vaccine to test the T-independent humoral response; an anti-meningococcal vaccine (group A, C, W135 and Y) CRM 197 oligosaccharide to test the T-cell response to a neoantigen. The primary endpoint was the proportion of patients showing a greater than 2-fold increase the tetanus IgG level in serum between the pre-vaccine period and 4 weeks post-vaccination. The proportion of responders was comparable on DMF and IFNβ (68% vs 73%). Responder rates were also comparable for all serotypes studied: diphertheria (58% vs 61%), pneumococcal serotype 3 (66% vs 79%) and serotype 8 (95% vs 88%), and meningococcal serogroup C (53% vs 53%). Patients were considered to have achieved adequate seroprotection according to the thresholds...
defined by the American Academy of Allergy, Asthma and Immunology [50].

**Recommendation 4d. Teriflunomide.** The vaccine response to influenza in patients treated with teriflunomide was decreased compared to MS patients treated with interferon beta (level B). The other vaccines were not studied. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 66; 95% [5–9]); Relative agreement (median 8, min–max 1–9, 30th–70th percentile: 8–9).

Data are based on 2 studies. The TERIVA (teriflunomide and vaccination) study [46] was a multicenter, multinational, parallel group study involving 128 patients in 3 arms, treated with teriflunomide 7 mg, 14 mg or IFNβ, receiving a single trivalent seasonal influenza vaccine injection (class 2 to 3). The vaccinal response in all 3 groups and for all strains was protective, but it was slightly lower in the 14 mg arm. In 2015, Bar-Or et al. performed a randomized, double-blind, placebo-controlled study (class 2). Twenty-three healthy subjects received teriflunomide (70 mg/day for 5 days then 14 mg/day for 25 days) and 23 received placebo for 30 days [51]. Anti-rabies antibody levels at D31 and D38 were lower than placebo-treated patients, but all subjects achieved a sufficient level of seroprotection. The study was not conducted on MS patients.

**Recommendation 4e. Mitoxantrone.** The vaccine response to influenza in patients treated with mitoxantrone was inadequate compared to that of healthy controls (level C). The other vaccines were not studied. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendation).

Rating: Appropriate (number of available scores: 65; 98% [5–9]); Relative agreement (median 9, min–max 1–9, 30th–70th percentile: 8–9).

In a Swedish cohort [44], none of the 11 MS patients on mitoxantrone were protected after vaccination against the influenza A H1N1 2009 strain (0/11 vs 94/216 healthy controls) and only one patient had detectable antibody titers against the 2010 H1N1 and H3N2 strains (1/4 vs 58/73 healthy controls). These results indicate that influenza vaccination while on mitoxantrone does not provide adequate protection.

**Recommendation 4f. Natalizumab.** The vaccine response in patients treated with natalizumab was reduced for influenza, but not for tetanus, compared to healthy controls (level B). The other vaccines were not studied. It is advised to apply the recommendations for immunization of immunocompromised patients. (expert recommendations).

Rating: Appropriate (number of available scores: 67; 97% [5–9]); Relative agreement (median 9, min–max 1–9, 30th–70th percentile: 8–9).

Three small studies have compared the efficacy of vaccines of different influenza strains in MS patients treated with natalizumab, compared to healthy controls [44,45,52]. All showed a decrease in the vaccinal response. Kaufman et al. evaluated the efficacy of a tetanus booster in 30 patients treated with natalizumab compared to 30 patients without treatment [53]. After one month, 100% of controls and 94% of patients receiving natalizumab were adequately immunized against tetanus.

**Recommendation 4g. Fingolimod.** The vaccine response in patients treated with fingolimod was reduced compared to healthy controls, untreated MS and interferon beta-treated patients (level B). It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 67; 99% [5–9]); Relative agreement (median 9, min–max 1–9, 30th–70th percentile: 8–9).

In a randomized clinical trial (class 1), Kappos et al. compared the vaccine responses to a trivalent influenza vaccine and to a tetanus booster in 93 fingolimod-treated MS patients and 43 placebo-treated patients [54]. The rate of responders to vaccination was lower in patients taking fingolimod at 3 and 6 weeks for influenza (54% vs 85% and 43% vs 75% respectively) and for tetanus (40% vs 61% and 38% vs 49%, respectively). Similar results were found in smaller and non-randomized studies for influenza [45,48,55,56].

Overall, these studies demonstrate a qualitative and quantitative decrease in the vaccine response in patients treated with fingolimod.

**Recommendation 4h. Alemtuzumab.** The data are insufficient to evaluate the vaccine response in patients treated with alemtuzumab. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 67; 97% [5–9]); Relative agreement (median 9, min–max 1–9, 30th–70th percentile: 8–9).

A single case-control pilot study [57] explored the immune competence in 24 patients after treatment with alemtuzumab (including 5 patients who had been vaccinated within 6 months of the last alemtuzumab infusions) by measuring the humoral response to 3 vaccines (the diphtheria-tetanus-polio vaccine, the conjugated Haemophilus influenza type B and meningococcus type C vaccine, and the polysaccharide pneumococcal vaccine). For meningococcus, 83% of MS patients
were immunized at 4 weeks compared to 100% of historical healthy controls. For Haemophilus influenza type B, 95% of the patients were immunized compared to 90% of the historical healthy controls. For the pneumococcal vaccine, the level of immunization was correct, except in a patient vaccinated within 2 months after treatment despite a weak vaccine response, suggesting a lack of effective immunization at this time.

**Recommendation 4i. Ocrelizumab.** The vaccine response in patients treated with ocrelizumab was effective but decreased after 12 weeks for tetanus, Pneumococcus and influenza compared with non-treated and interferon beta-treated MS (level B). It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 65; 98% [5–9]); Relative agreement (median 9, min–max 8–9, 30th–70th percentile: 8–9).

There is only one study, the results of which were only presented orally at the American Academy of Neurology in April 2018 (VELOCE study) [58]. This was a phase IIIb clinical trial evaluating the vaccine response of MS patients exposed to ocrelizumab (class 1). Responses to 5 vaccines or neoantigens were evaluated, each selected because of the different mechanisms of the immunological response. Two-thirds of the patients were randomized to the ocrelizumab group, one-third to placebo or the IFNβ group. The vaccines were administered from the 12th week of the 1st cycle of treatment with ocrelizumab. The IgG response to a tetanus antigen was decreased in ocrelizumab compared to the control group (subjects without treatment or IFNβ treatment) but remained on average above the protective threshold. The percentage of patients who achieved a positive response was decreased at 4 and 8 weeks compared to controls, respectively 24.2% vs 60.6% at 4 weeks and 23.9% vs 54.5% at 8 weeks. For the pneumococcal IgG response, the percentage of patients who achieved a positive response was decreased for all serotypes studied at 4 weeks, but with 86.6% having a positive response to at least 2 serotypes, 77.6% to 4 serotypes and 37.3% to at least 12 serotypes. Seroprotection against influenza was also decreased but varied between 55.6 and 80.0% of subjects protected with ocrelizumab, depending on the strain. The neoantigen response was decreased for both IgM and IgG compared to untreated and IFNβ-treated patients. No vaccine safety issues were reported during the study. One of the limitations of the study was the lack of data on vaccine responses in patients with longer exposure, which can be assumed, at least for the B-cell response, to decrease with an increased duration of treatment exposure.

In conclusion, this study showed a decreased humoral response to vaccines during treatment with ocrelizumab, but with protective thresholds reached, particularly for the influenza vaccine, in a significant percentage of patients.

**Recommendation 4j. Cladribine.** No vaccine has been studied in patients with MS treated with cladribine. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 65; 100% [5–9]); Relative agreement (median 9, min–max 5–9, 30th–70th percentile: 9–9).

There is no data in the literature for patients with MS or other conditions.

**Recommendation 4k. Cyclophosphamide (off-label).** No vaccine has been studied in patients with MS treated with cyclophosphamide. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 66; 100% [5–9]); Relative agreement (median 9, min–max 5–9, 30th–70th percentile: 9–9).

There is no data in the literature concerning MS patients. A study on ovarian cancer showed a decrease in vaccine efficiency [59].

**Recommendation 4l. Methotrexate (off-label).** No vaccine has been studied in patients with MS treated with methotrexate. The vaccine response in patients with rheumatoid arthritis treated with methotrexate was satisfactory. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).

Rating: Appropriate (number of available scores: 69; 99% [5–9]); Relative agreement (median 9, min–max 4–9, 30th–70th percentile: 8–9).

There is no data in the literature concerning MS patients. Available data come from studies of patients treated for other autoimmune diseases [60,61]. For patients with rheumatological autoimmune diseases, infections have been shown to be more frequent while on methotrexate, but results are confounded also by the older age of patients and the history of corticosteroid or immunosuppressive therapy [62].

**Recommendation 4m. Azathioprine/mycophenolate mofetil (off-label).** No vaccine has been studied in patients with MS treated with azathioprine or mycophenolate mofetil. It is advised to apply the recommendations for immunization of immunocompromised patients (expert recommendations).
3.5. Question 5: What prevention methods should be offered to patients with MS?

Recommendation 5a. The vaccination schedule of the general population should be applied to any patient with MS unless there is a specific contraindication (recommendation of the Haut Conseil de la Santé Publique, article L3111-1, Code de la Santé Publique, fig. 1). 63

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Strong agreement (median 9, min–max 7–9, 30th–70th percentile: 9–9).

Recommendation 5b. It is recommended to update the vaccination schedule as soon as possible after the diagnosis of MS and before any disease-modifying treatment is introduced (recommendation of the Haut Conseil de la Santé Publique, article L3111-1, Code de la Santé Publique). 63

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Relative agreement (median 9, min–max 2–9, 30th–70th percentile: 9–9).

Recommendation 5c. Seasonal flu vaccination is recommended for patients with MS who are treated with immunosuppressive drugs or who have a significant disability (or any other reason recommended for influenza vaccination) unless there is a specific contraindication (recommendation of the Haut Conseil de la Santé Publique, article L3111-1, Code de la Santé Publique). 63–64 For the other MS patients, seasonal flu vaccination can be proposed annually (expert recommendations)

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Strong agreement (median 9, min–max 7–9, 30th–70th percentile: 9–9).

Recommendation 5d. There is no restriction for vaccines associated with immunomodulators (interferon beta and glatiramer acetate) (level B)

Rating: Appropriate (number of available scores: 71; 100% [5–9]); Relative agreement (median 9, min–max 2–9, 30th–70th percentile: 9–9).

---

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>1 month</th>
<th>2 months</th>
<th>4 months</th>
<th>6 months</th>
<th>12 months</th>
<th>18 months</th>
<th>6 years</th>
<th>11-13 years</th>
<th>14 years</th>
<th>25 years</th>
<th>45 years</th>
<th>65 years and more</th>
</tr>
</thead>
<tbody>
<tr>
<td>diphtheria-tetanus-polio</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hepatitis b</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>meningococcus c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>measles-mumps-rubella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| human papillomaviruses (HPV) | | | | | | | | | | | | 2 doses at 0 and 6 months
| seasonal influenza | | | | | | | | | | | | every year
| shingles | | | | | | | | | | | | every 10 years

Fig. 1 – French 2018 vaccination schedule (adapted from Calendrier des vaccinations et recommandations vaccinales 2018. Ministère de la Santé http://solidarites-sante.gouv.fr/IMG/pdf/calendrier_vaccinations_2018.pdf).
It is not recommended to vaccinate during a relapse requiring high dose steroid therapy (expert recommendation).

Rating: Appropriate (number of available scores: 71; 99% [5–9]); Relative agreement (median 9, min–max 4–9, 30th–70th percentile: 9–9).

**Recommendation 5f. It is recommended to provide the immediate entourage of an immunocompromised person with the vaccination schedule, seasonal influenza vaccination and varicella vaccination in case of negative serology (recommendation of the Haut Conseil de la Sante´ Publique, article L3111-1, Code de la Sante´ Publique). [63–64]**

In 2002 the first recommendations into the vaccination program for MS patients were issued [65]. The recommendations highlighted the safety of vaccines in this disease, thus encouraging compliance with the same immunization schedule as that of the general population, whether patients were treated or not (mainly injectable immunomodulators at that time). However, these first recommendations did not address the interaction with the most recent DMTs: immunosuppressants or biotherapies. One paper only addressed the question of response can come from recommendations made for patients with rheumatic diseases in particular. Nevertheless, these auto-immune diseases can themselves contribute to immunosuppression, which is not the case in MS. It is therefore difficult to fully extrapolate these data to patients with MS on DMTs. However, immunosuppression induced by new MS treatments requires evaluation of the risk of infection that can be more serious because of the occurrence in the context of a debilitating and weakened condition, and to consider the possibility of prevention.

In France, official recommendations of the Haut Conseil pour la Sante´ Publique (High Council for Public Health) are updated and published every year [63]. They describe the vaccination schedule for the general population, but since 2014 they also include a specific section for immunocompromised and asplenic patients, targeting all autoimmune and inflammatory diseases [64]. Therefore they apply also to MS patients, especially when treated with DMTs.

Beside all the other important and very practical points described in these recommendations one is of particular interest in MS: “During steroid therapy, the administration of a live vaccine is contraindicated beyond the following doses and durations (immunosuppressive corticosteroid therapy):

- in adults: 10 mg of prednisone equivalent per day, for more than two weeks;
- in children: 2 mg/kg of prednisone equivalent per day (and more than 20 mg per day in children over 10 kg), for more than two weeks;
- “Boluses” of corticosteroids contraindicate the administration of a live vaccine for the next three months.”

4. Highlights

Vaccines have been suspected in the past to trigger MS and MS exacerbations. With the extension of the immunomodulatory treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients. The French Group for Recommendations in Multiple Sclerosis (France4MS) performed a systematic search for papers from Medline and other university databases (January 1975–June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS.

Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infections and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs.

**Endorsement**

The 2019 recommendations on immunization and multiple sclerosis have been organized by the French Multiple Sclerosis Society (Societe´ Francophone de la Sclero´se en Plaques [SFSEP]).
They are also endorsed by the French Neurological Society (Société Française de Neurologie [SFN]), the French Federation of Neurology (Fédération Française de Neurologie [FFN]) and the Vaccines and Prevention group of the French Society for Infectious Diseases (Société de Pathologies Infectieuses de Langue Française [SPIFL]).

An extensive French version including tables describing all contributing studies is available on sfsep.org/vaccination.

A tutorial iOS application SFSEP is available on AppStore.

Study funding

None.

Author contribution

Dr. Lebrun - study concept and design, acquisition of data, analysis and interpretation, writing.

Dr. Vukusic - study concept and design, acquisition of data, analysis and interpretation, writing.

Dr. Lebrun has received lecturing fees, travel grants and research support from Sanofi-Genzyme, the manufacturer of the vaccines that are described in this study.

Dr. Vukusic has received lecturing fees, travel grants and research support from Sanofi-Genzyme, the manufacturer of the vaccines that are described in this study.

Steering committee

Christine Lebrun-Frenay (Nice, co-chair), Sandra Vukusic (Lyon, co-chair), Jérôme De Seze (Strasbourg, co-chair);
Supervision of readers: Xavier Ayrignac (Montpellier), Caroline Benso (Paris), Emmanuelle Le Page (Rennes), Jean-Christophe Ouallet (Bordeaux), Eric Thouvenot (Nimes), Helène Zephir Bensa (Paris), Emmanuelle Le Page (Rennes), Jean-Christophe Supervision of readers: Xavier Ayrignac (Montpellier), Caroline Benso (Paris), Emmanuelle Le Page (Rennes), Jean-Christophe Ouallet (Bordeaux), Eric Thouvenot (Nimes), Helène Zephir Bensa (Paris), Emmanuelle Le Page (Rennes), Jean-Christophe

Rating group

Bertrand Audoin (Marseille), Eric Berger (Besançon), Patricia Bernady (Bayonne), David Brassat (Toulouse), Bruno Brochet (Bordeaux), Philippe Cabre (Fort de France), Jean Philippe Camdessanché (Saint Etienne), Marc Coustans (Saint Malo), Marc Debouverie (Nancy), Gilles Edan (Rennes), Ziad Elias (Toulon), Jean Marc Faucheux (Agens), Olivier Gout (Paris), Patrick Hautecoeur (Lomme), Olivier Heinzlef (Poissy-Saint Germain), Pierre Labauge (Montpellier), David Laplaud (Nantes), Emmanuelle Leray (Rennes), Laurent Magy (Limoges), Claude Mekies (Toulouse), Marc Merienne (Saint Malo), Thibaut Moreau (Dijon), Caroline Papeix (Paris), Evelyne Planque (Epinal), Jean Pelletier (Marseille), Bruno Stankhof (Paris), Patricia Tournaire (Avignon), Patrick Vermersch (Lille).

Reading group

Victor Abadie (Chalon), Abdullatif Alkhedr (Amiens), Florence Ader (Lyon), Catherine Achour (Metz), Haili Alchaar (Nice), Frédéric Andreux (Bourges), Géraldine Andriodias (Lyon), Roxane Arjmand (Dijon), Dominique Audry (Chalon sur saone), Dominique Aufauvre ( Clermont-Ferrand), Charles Autreux (Lille), Marc Baille (Montpellier), Michel Benazet (Toulouse), Djamel Bensmail (Garches), Yann Bertaga (Bastia), Damien Biotti (Toulouse), Anne Blanchard-Dauphin (Lille), Julien Bonenfant (Rennes), Mikael Bonnaf (Pau), Bernard Bonnemain (Nantes), Florent Borgel (Grenoble), Elisabeth Botelho-Nevers (St Etienne), Ségoélone Bouly (Bagnol), Clémence Boutière (Marseille), Pierre Branger (Caen), Saskia Breesch (Nice), Véronique Breuil (Nice), Hélène Brugéilles (Paris), Pierre Bugnon (Dijon), Clarisse Carra-Dalière (Montpellier), Jean-Marie Chamounard (Paris), Bénédicte Chassande (Orleans), Pauline Chataignier (Brive), Mohamed Chibicheb (Narbonne), Amandine Chenet (Nantes), Pierre Clavelou (Clermont-Ferrand), Renato Colamarino (Vichy), Irène Coman (Bobigny), Patrick-René Corail (Martinique), Sylvie Courtos (Mulhouse), Alain Creange (Créteil), Éric Creisson (Toulouse), Nathalie Daluzeau (Lisieux) Jérôme de Seze (Strasbourg), Raphael Depaz (Paris), Lucas Divio (Dijon), Xavier Douay (Lille), Cécile Dulau (Bordeaux), Françoise Durand-Dubief (Lyon), Ombeline Fagniez (Poissy), Marc Faucher (Bruges), Manuela Fournier (Nice), Amandine Gagneux-Brunon (Saint Etienne), Philippe Gaida (Bordeaux), Paola Galli (Martinique), Philippe Gallien (Rennes), Joel Gaudelus (Paris), Dominique Gault (Strasbourg), Annick Gayou (Talence), Margaux Genevray (Rennes), Arnaud Gentil (Dijon), Julien Géry (Chambery), Laurence Gignoux (Lyon), Marianne Giroux (Valenciennes), Pascale Givron (Clermont-Ferrand), Jérôme Grimard (Chartres), Anne-Marie Guennoc (Tours), Marie Jaeger (Grenoble), Séverine Jeannin (Martinique), Laurent Kremer (Strasbourg), Arnaud Kwiatkowski (Lomme), Celine Labeyrie (Kremlin Bicetre), Sylvain Lachaud (Cannes), Isabelle Laffont (Montpellier), Caroline Lacintin-Garcia (Nantes), Julien Lannoy (Lille), Livia Lanotte (Strasbourg), Dominique Latombe (Lyons), Michel Lauzeral (Clermont-Ferrand), Pascal Lejeune (La roche sur Yon), Philippe Lejoyeux (Bourg-en-bresse), Benjamin Lemonnier (Breteville), Catherine Lubetzki (Paris), Catherine-Marie Loche (Creteil), Berro Mada (Caen), Eric Manchon (Gonesse), Romain Marignier (Lyons), Philippe Marque (Toulouse), Aude Maurousset (Tours), André-Michel Milor (Limosges), Xavier Moisset (Clermont-Ferrand), Alexis Montcuquet (Limosges), Nathalie MOREL (Annecy), Mohsen Moussa (Limosges), Jean-Pierre Naudillon (Bordeaux), Marie Normand (Toulouse), Pascal Olive (Martinique), Olivier Outterryck (Lille), Clément Pacault (Grenoble), Ivanía Patry (Fontenay sous bois), Delphine Peaureau (Toulouse), Bertrand Pichon (Paris), Marie-Caroline Naudillon (Bordeaux), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Toulouse), Marie Normand (Tou
Pouget (Lyon), Valérie Pourcher (Paris), Caroline Radot (Hôpitaux d’Hyères; Isabelle Robert (Rennes), Fanny Rocher (Nice), Alexis Ruet (Caen), Claude Saint-Val (Paris), Jean-Yves Salle (Limoges), Anne Salmon (Rennes), Eric Sartori (Lorient), Stéphane Schaeffer (Caen), Frédéric Taithe (Clermont-Ferrand), Christophe Tizon (Villeneuve St Georges), Ayman Toubah (Creteil), Marie-Hélène Warter (Strasbourg), Basile Wittwer (Metz), Benjamin Wiplosz (Paris), Christophe Zaenker (Strasbourg).

Acknowledgement

We are extremely grateful to Mrs. Florence Bouriot and Mrs Caroline Giroudon, librarians at the Hospices Civils de Lyon for their assistance in the documentary research, and to Mrs Nathalie Freynet and Dr Gérard Lairy (Affinité Santé) for their methodological support.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at http://doi.dx.org/10.1016/j.neurol.2019.04.001.

REFERENCES


Pekmezovic T, Jarebinski M, Drulovic J. Childhood.


McNicholas N, Chataway J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 2011;258:1545–7.


